rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
7
|
pubmed:dateCreated |
2005-7-18
|
pubmed:abstractText |
FR900098 represents a derivative of the new antimalarial drug fosmidomycin with enhanced activity. The mechanism of action is the inhibition of the 1-desoxy-D-xylulose 5-phosphate (DOXP) reductoisomerase, an essential enzyme of the mevalonate independent pathway of isoprenoid biosynthesis. Prodrugs with increased oral activity in mice infected with the rodent malaria parasite Plasmodium vinckei were obtained by masking the phosphonate moiety of FR900098 as alkoxycarbonyloxyethyl esters.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0365-6233
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
338
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
305-14
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:15996004-Administration, Oral,
pubmed-meshheading:15996004-Aldose-Ketose Isomerases,
pubmed-meshheading:15996004-Animals,
pubmed-meshheading:15996004-Antimalarials,
pubmed-meshheading:15996004-Biological Availability,
pubmed-meshheading:15996004-Dose-Response Relationship, Drug,
pubmed-meshheading:15996004-Fosfomycin,
pubmed-meshheading:15996004-Malaria,
pubmed-meshheading:15996004-Mice,
pubmed-meshheading:15996004-Mice, Inbred BALB C,
pubmed-meshheading:15996004-Multienzyme Complexes,
pubmed-meshheading:15996004-Oxidoreductases,
pubmed-meshheading:15996004-Plasmodium,
pubmed-meshheading:15996004-Prodrugs,
pubmed-meshheading:15996004-Quantitative Structure-Activity Relationship
|
pubmed:year |
2005
|
pubmed:articleTitle |
Alkoxycarbonyloxyethyl ester prodrugs of FR900098 with improved in vivo antimalarial activity.
|
pubmed:affiliation |
Department für Pharmazie, Ludwig-Maximilians-Universität, München, Germany.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|